Skip to main content
Bulletin of the National Research Centre

Table 3 Pharmacokinetics properties of the potential inhibitors from swissadme server

From: Prospect into therapeutic potentials of Moringa oleifera phytocompounds against cancer upsurge: de novo synthesis of test compounds, molecular docking, and ADMET studies

Compound ID GI absorption BBB permeant Pgp substrate CYP1A2 inhibitor CYP2C19 inhibitor CYP2C9 inhibitor CYP2D6 inhibitor CYP3A4 inhibitor
ML2 Low Yes No No No No No No
ML4 High Yes No Yes No No Yes No
ML5 High Yes No No No No Yes No
ML6 High Yes No Yes No No No No
ML7 Low No Yes No No Yes No No
ML8 High Yes No Yes No No No No
ML9 Low No Yes No No No No No
ML10 Low No Yes No No Yes No No
ML11 High No No Yes No Yes No No
ML12 Low No No Yes No Yes No No
ML13 Low No Yes No No No No No
ML14 High No No Yes No Yes No No
ML15 High No No No No No No Yes
MS1 High Yes No Yes No No No No
MS2 Low No Yes No No No No No
MS3 High No No Yes No No No No
MS4 High No No Yes No Yes No No
MS5 High Yes No Yes No Yes No No
  1. GI gastrointestinal, BBB blood–brain barrier, Pgp P-glycoprotein, CYP Cytochrome P
Back to article page